Titre : Chrysosporium

Chrysosporium : Questions médicales fréquentes

Termes MeSH sélectionnés :

Mutation
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Chrysosporium : Questions médicales les plus fréquentes", "headline": "Chrysosporium : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Chrysosporium : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-07", "dateModified": "2025-05-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Chrysosporium" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Deuteromycota", "url": "https://questionsmedicales.fr/mesh/D003904", "about": { "@type": "MedicalCondition", "name": "Deuteromycota", "code": { "@type": "MedicalCode", "code": "D003904", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B01.300.381" } } }, "about": { "@type": "MedicalCondition", "name": "Chrysosporium", "alternateName": "Chrysosporium", "code": { "@type": "MedicalCode", "code": "D002912", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Anwei Chen", "url": "https://questionsmedicales.fr/author/Anwei%20Chen", "affiliation": { "@type": "Organization", "name": "College of Resources and Environment, Hunan Agricultural University, Changsha 410128, PR China. Electronic address: A.Chen@hunau.edu.cn." } }, { "@type": "Person", "name": "Liang Hu", "url": "https://questionsmedicales.fr/author/Liang%20Hu", "affiliation": { "@type": "Organization", "name": "School of Minerals Processing and Bioengineering, Key Laboratory of Biohydrometallurgy of Ministry of Education, Central South University, Changsha 410083, China. Electronic address: huliang2018@csu.edu.cn." } }, { "@type": "Person", "name": "Sheng-Tao Yang", "url": "https://questionsmedicales.fr/author/Sheng-Tao%20Yang", "affiliation": { "@type": "Organization", "name": "College of Chemistry and Environment Protection Engineering, Southwest Minzu University, Chengdu, 610041, PR China. Electronic address: yangst@pku.edu.cn." } }, { "@type": "Person", "name": "Ni He", "url": "https://questionsmedicales.fr/author/Ni%20He", "affiliation": { "@type": "Organization", "name": "School of Minerals Processing and Bioengineering, Key Laboratory of Biohydrometallurgy of Ministry of Education, Central South University, Changsha 410083, China." } }, { "@type": "Person", "name": "Motoyuki Shimizu", "url": "https://questionsmedicales.fr/author/Motoyuki%20Shimizu", "affiliation": { "@type": "Organization", "name": "Department of Applied Biological Chemistry, Faculty of Agriculture, Meijo University, Nagoya, Aichi 468-8502, Japan. Electronic address: moshimi@meijo-u.ac.jp." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.", "datePublished": "2023-06-14", "url": "https://questionsmedicales.fr/article/37314501", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00280-023-04545-4" } }, { "@type": "ScholarlyArticle", "name": "A novel RBBP8(p.E281*) germline mutation is a predisposing mutation in familial hereditary cancer syndrome.", "datePublished": "2023-08-24", "url": "https://questionsmedicales.fr/article/37615686", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00109-023-02354-z" } }, { "@type": "ScholarlyArticle", "name": "Mutation-Attention (MuAt): deep representation learning of somatic mutations for tumour typing and subtyping.", "datePublished": "2023-07-07", "url": "https://questionsmedicales.fr/article/37420249", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13073-023-01204-4" } }, { "@type": "ScholarlyArticle", "name": "Mutation spectrum of Kallmann syndrome: identification of five novel mutations across ANOS1 and FGFR1.", "datePublished": "2023-03-01", "url": "https://questionsmedicales.fr/article/36859276", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12958-023-01074-w" } }, { "@type": "ScholarlyArticle", "name": "Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.", "datePublished": "2022-06-11", "url": "https://questionsmedicales.fr/article/35690645", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41379-022-01118-3" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Eucaryotes", "item": "https://questionsmedicales.fr/mesh/D056890" }, { "@type": "ListItem", "position": 3, "name": "Champignons", "item": "https://questionsmedicales.fr/mesh/D005658" }, { "@type": "ListItem", "position": 4, "name": "Deuteromycota", "item": "https://questionsmedicales.fr/mesh/D003904" }, { "@type": "ListItem", "position": 5, "name": "Chrysosporium", "item": "https://questionsmedicales.fr/mesh/D002912" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Chrysosporium - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Chrysosporium", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Chrysosporium", "description": "Comment diagnostiquer une infection par Chrysosporium ?\nQuels tests sont utilisés pour identifier Chrysosporium ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels symptômes indiquent une infection par Chrysosporium ?\nPeut-on utiliser des tests sérologiques pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Mutation&page=8#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Chrysosporium", "description": "Quels sont les symptômes courants d'une infection fongique ?\nLes infections cutanées par Chrysosporium sont-elles fréquentes ?\nComment se manifestent les infections pulmonaires ?\nLes infections systémiques sont-elles graves ?\nLes symptômes varient-ils selon l'âge ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Mutation&page=8#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Chrysosporium", "description": "Comment prévenir les infections par Chrysosporium ?\nLes personnes immunodéprimées doivent-elles prendre des précautions ?\nLe port de gants est-il recommandé lors de manipulations ?\nLes vaccinations aident-elles à prévenir ces infections ?\nL'hygiène personnelle joue-t-elle un rôle dans la prévention ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Mutation&page=8#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Chrysosporium", "description": "Quels traitements sont efficaces contre Chrysosporium ?\nLes traitements varient-ils selon la gravité de l'infection ?\nCombien de temps dure le traitement antifongique ?\nDes effets secondaires sont-ils associés aux antifongiques ?\nLes infections par Chrysosporium nécessitent-elles une hospitalisation ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Mutation&page=8#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Chrysosporium", "description": "Quelles complications peuvent survenir avec Chrysosporium ?\nLes infections par Chrysosporium peuvent-elles être mortelles ?\nComment les complications sont-elles gérées ?\nLes complications affectent-elles le pronostic ?\nLes infections récurrentes sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Mutation&page=8#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Chrysosporium", "description": "Quels sont les principaux facteurs de risque d'infection ?\nLes personnes âgées sont-elles plus à risque ?\nLe diabète augmente-t-il le risque d'infection fongique ?\nLes traitements immunosuppresseurs sont-ils un facteur de risque ?\nLes voyages dans des zones tropicales augmentent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D002912?mesh_terms=Mutation&page=8#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection par Chrysosporium ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen microscopique et la culture du champignon." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour identifier Chrysosporium ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de culture et des techniques moléculaires comme la PCR peuvent être utilisés." } }, { "@type": "Question", "name": "Les biopsies sont-elles nécessaires pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des biopsies peuvent être nécessaires pour confirmer l'infection fongique." } }, { "@type": "Question", "name": "Quels symptômes indiquent une infection par Chrysosporium ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des lésions cutanées, des infections pulmonaires ou systémiques." } }, { "@type": "Question", "name": "Peut-on utiliser des tests sérologiques pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les tests sérologiques ne sont généralement pas fiables pour Chrysosporium." } }, { "@type": "Question", "name": "Quels sont les symptômes courants d'une infection fongique ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fièvre, toux, éruptions cutanées et fatigue." } }, { "@type": "Question", "name": "Les infections cutanées par Chrysosporium sont-elles fréquentes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent provoquer des lésions cutanées et des démangeaisons." } }, { "@type": "Question", "name": "Comment se manifestent les infections pulmonaires ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles se manifestent par une toux persistante, des douleurs thoraciques et des difficultés respiratoires." } }, { "@type": "Question", "name": "Les infections systémiques sont-elles graves ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent être graves et nécessitent une attention médicale immédiate." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de l'âge et de l'état immunitaire." } }, { "@type": "Question", "name": "Comment prévenir les infections par Chrysosporium ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter l'exposition à des environnements humides et à des matériaux contaminés aide à prévenir." } }, { "@type": "Question", "name": "Les personnes immunodéprimées doivent-elles prendre des précautions ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles doivent éviter les environnements à risque et consulter un médecin régulièrement." } }, { "@type": "Question", "name": "Le port de gants est-il recommandé lors de manipulations ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le port de gants lors de la manipulation de terre ou de matériaux potentiellement contaminés est conseillé." } }, { "@type": "Question", "name": "Les vaccinations aident-elles à prévenir ces infections ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Non, il n'existe pas de vaccin spécifique contre les infections par Chrysosporium." } }, { "@type": "Question", "name": "L'hygiène personnelle joue-t-elle un rôle dans la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une bonne hygiène personnelle peut réduire le risque d'infections fongiques." } }, { "@type": "Question", "name": "Quels traitements sont efficaces contre Chrysosporium ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les antifongiques comme l'itraconazole et le voriconazole sont souvent utilisés." } }, { "@type": "Question", "name": "Les traitements varient-ils selon la gravité de l'infection ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections légères peuvent être traitées par voie orale, tandis que les cas graves nécessitent une perfusion." } }, { "@type": "Question", "name": "Combien de temps dure le traitement antifongique ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La durée du traitement peut varier de plusieurs semaines à plusieurs mois selon la gravité." } }, { "@type": "Question", "name": "Des effets secondaires sont-ils associés aux antifongiques ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme des nausées, des éruptions cutanées et des problèmes hépatiques peuvent survenir." } }, { "@type": "Question", "name": "Les infections par Chrysosporium nécessitent-elles une hospitalisation ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Cela dépend de la gravité de l'infection; les cas graves peuvent nécessiter une hospitalisation." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec Chrysosporium ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections systémiques graves et des lésions pulmonaires." } }, { "@type": "Question", "name": "Les infections par Chrysosporium peuvent-elles être mortelles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en particulier chez les personnes immunodéprimées, elles peuvent être fatales." } }, { "@type": "Question", "name": "Comment les complications sont-elles gérées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications nécessitent souvent des traitements antifongiques intensifs et un suivi médical." } }, { "@type": "Question", "name": "Les complications affectent-elles le pronostic ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la présence de complications peut aggraver le pronostic et prolonger la durée de traitement." } }, { "@type": "Question", "name": "Les infections récurrentes sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des infections récurrentes peuvent survenir, surtout chez les patients immunodéprimés." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'infection ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'immunodépression, le diabète et l'exposition à des environnements humides." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées ont un risque accru en raison d'un système immunitaire affaibli." } }, { "@type": "Question", "name": "Le diabète augmente-t-il le risque d'infection fongique ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète peut affaiblir le système immunitaire et augmenter le risque d'infections." } }, { "@type": "Question", "name": "Les traitements immunosuppresseurs sont-ils un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements immunosuppresseurs augmentent le risque d'infections fongiques." } }, { "@type": "Question", "name": "Les voyages dans des zones tropicales augmentent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les voyages dans des zones tropicales peuvent exposer à des agents pathogènes fongiques." } } ] } ] }

Sources (10000 au total)

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.

Aberrant alterations of ERBB receptor tyrosine kinases lead to tumorigenesis. Single agent therapy targeting EGFR or HER2 has shown clinical successes, but drug resistance often develops due to aberra... Patients with actionable somatic mutations or amplifications in ERBB genes or actionable KRAS mutations were enrolled to receive neratinib and trametinib in this phase I dose escalation trial. The pri... Twenty patients were enrolled with a median age of 50.5 years and a median of 3 lines of prior therapy. Grade 3 treatment-related toxicities included: diarrhea (25%), vomiting (10%), nausea (5%), fati... Neratinib and trametinib combination was toxic and had limited clinical efficacy. This may be due to suboptimal drug dosing given drug-drug interactions.... NCT03065387....

Mutation-Attention (MuAt): deep representation learning of somatic mutations for tumour typing and subtyping.

Cancer genome sequencing enables accurate classification of tumours and tumour subtypes. However, prediction performance is still limited using exome-only sequencing and for tumour types with low soma... We introduce here Mutation-Attention (MuAt), a deep neural network to learn representations of simple and complex somatic alterations for prediction of tumour types and subtypes. In contrast to many p... We trained MuAt models on 2587 whole cancer genomes (24 tumour types) from the Pan-Cancer Analysis of Whole Genomes (PCAWG) and 7352 cancer exomes (20 types) from the Cancer Genome Atlas (TCGA). MuAt ... Integrated representations of somatic alterations learnt by MuAt were able to accurately identify histological tumour types and identify tumour entities, with potential to impact precision cancer medi...

Mutation spectrum of Kallmann syndrome: identification of five novel mutations across ANOS1 and FGFR1.

Kallmann syndrome (KS) is a common type of idiopathic hypogonadotropic hypogonadism. To date, more than 30 genes including ANOS1 and FGFR1 have been identified in different genetic models of KS withou... A total of 35 unrelated patients with clinical features of disorder of sex development were recruited. Custom-panel sequencing or whole-exome sequencing was performed to detect the pathogenic mutation... ANOS1 gene c.709 T > A and c.711 G > T were evaluated as pathogenic by several commonly used software, and c.1063-2 A > T was verified by transcriptional splicing assay. The c.1063-2 A > T mutation ac... Herein, we identified three novel ANOS1 mutations and two novel FGFR1 variations in Chinese KS families. In silico prediction and functional experiment evaluated the pathogenesis of ANOS1 mutations. F...

The identification and analysis of meristematic mutations within the apple tree that developed the RubyMac sport mutation.

Understanding the molecular basis of sport mutations in fruit trees has the potential to accelerate generation of improved cultivars.... For this, we analyzed the genome of the apple tree that developed the RubyMac phenotype through a sport mutation that led to the characteristic fruit coloring of this variety. Overall, we found 46 som... Our analysis revealed insights in the characteristics of somatic change, which not only included de novo mutations but also gene conversions. Some of these somatic changes displayed strong candidate m...

Evolutionary dependency of cancer mutations in gene pairs inferred by nonsynonymous-synonymous mutation ratios.

Determining the impact of somatic mutations requires understanding the functional relationship of genes acquiring mutations; however, it is largely unknown how mutations in functionally related genes ... We employed non-synonymous-to-synonymous or dNdS ratios to evaluate the evolutionary dependency (ED) of gene pairs, assuming a mutation in one gene of a gene pair can affect the evolutionary fitness o... We propose that dNdS ratios of gene pairs and their derived cdNS (context-dependent dNdS) scores as measure of ED distinguishing gene pairs either as synergistic (SYN) or antagonistic (ANT). Mutation ... We propose that the ED of gene pairs evaluated by dNdS ratios can advance our understanding of the functional relationship of genes with potential biological and clinical implications....

Genomic dissection and mutation-specific target discovery for breast cancer PIK3CA hotspot mutations.

Recent advancements in high-throughput genomics and targeted therapies have provided tremendous potential to identify and therapeutically target distinct mutations associated with cancers. However, to... In this study, we developed a functional genomic analysis workflow with a unique isogenic cell line panel bearing two distinct hotspot PIK3CA mutations, E545K and H1047R, to accurately identify target... Using our multi-modal genomics framework, we discover distinct differences in genomic regulation between PIK3CA hotspot mutations, suggesting the PIK3CA mutations have different regulatory effects on ...